Recruiting

Comparing a new psoriasis medication with an approved version

Plain-English translation of NCT07258745 on ClinicalTrials.gov ↗ · Source last updated December 2025 · Translation generated June 2026 · How we translate trials

Read our Psoriasis research guide →

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This trial is testing a new medication called , which is designed to work the same way as an already-approved psoriasis treatment called . Researchers want to make sure the new medication behaves identically in the body and is safe and well-tolerated. The study will compare how performs against two existing versions of the approved treatment.

Medications like can be expensive and difficult for some patients to access. This trial is testing whether the new treatment can offer a more affordable alternative while working just as safely and effectively.

Do you qualify?

You likely qualify if…

you are between 18 and 55 years old
you are in good overall health with no serious medical conditions
you are willing to receive a single injection and stay at a clinical facility for observation
you are not pregnant, not breastfeeding, and willing to use effective birth control during the study
you smoke 10 or fewer cigarettes per week and are willing to limit alcohol use

You likely don't qualify if…

you have ever received a similar psoriasis medication before
you have hepatitis B, hepatitis C, HIV, or active tuberculosis
you have had major surgery in the past 3 months or have a history of cancer in the past 5 years
you have active infections or a serious psychiatric condition that would affect your ability to participate
you have significant allergies to the medication or its ingredients

What participation looks like

You will receive a single injection of the medication in a pre-filled syringe at a clinical research facility. You will need to stay at the facility for observation and blood work after receiving the injection to monitor how your body responds. The study team will check your blood work several times and ask about any side effects you experience during your follow-up visits over the coming weeks.

AI-generated summary from trial data · Jun 2, 2026 · Not medical advice

Trial locations(1 site)

Poland